Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
暂无分享,去创建一个
Rainer König | Axel Benner | Barbara Hero | Benedikt Brors | Filip Pattyn | Matthias Fischer | Tim Beissbarth | Tobias Bauer | Frank Westermann | Jo Vandesompele | Manfred Schwab | F. Westermann | M. Schwab | T. Beißbarth | J. Vandesompele | M. Fischer | A. Oberthuer | B. Hero | R. König | B. Brors | A. Benner | F. Pattyn | D. Muth | K. Henrich | Kai-Oliver Henrich | André Oberthuer | T. Bauer | Daniel Muth | T. Beissbarth | Tobias Bauer
[1] Martin Vingron,et al. Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.
[2] Y. Benjamini,et al. THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .
[3] Andreas Prlic,et al. Ensembl 2007 , 2006, Nucleic Acids Res..
[4] J. Olson,et al. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. , 2006, Cancer research.
[5] M. Tuchman,et al. A population-based study of the usefulness of screening for neuroblastoma , 1996, The Lancet.
[6] Filip Pattyn,et al. Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation , 2004, Laboratory Investigation.
[7] Sergio Contrino,et al. ArrayExpress—a public repository for microarray gene expression data at the EBI , 2004, Nucleic Acids Res..
[8] J. Maris,et al. Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification , 2008, Oncogene.
[9] Richard A Young,et al. Chromatin immunoprecipitation and microarray-based analysis of protein location , 2006, Nature Protocols.
[10] Giacomo Finocchiaro,et al. Myc-binding-site recognition in the human genome is determined by chromatin context , 2006, Nature Cell Biology.
[11] F. Berthold,et al. Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. , 2003, Cancer letters.
[12] Patrick Warnat,et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Lutz,et al. E2F Proteins Regulate MYCN Expression in Neuroblastomas* , 2003, The Journal of Biological Chemistry.
[14] Teuvo Kohonen,et al. Self-Organizing Maps , 2010 .
[15] Jelle J. Goeman,et al. Testing association of a pathway with survival using gene expression data , 2005, Bioinform..
[16] J. Khan,et al. High Skp2 Expression Characterizes High-Risk Neuroblastomas Independent of MYCN Status , 2007, Clinical Cancer Research.
[17] M. Schwab,et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. , 1996, Oncogene.
[18] M. Schwab,et al. MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells , 1998, Oncogene.
[19] T. Sawada,et al. MASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPAN Interim Report of a Mass Screening Study Group , 1984, The Lancet.
[20] S. Berg,et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death , 2006, Molecular Cancer Therapeutics.
[21] M. Schwab,et al. Suppression of MYC by high expression of NMYC in human neuroblastoma cells , 1989, Journal of neuroscience research.
[22] Hans Clevers,et al. The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells , 2002, Cell.
[23] U. Kees,et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. , 2006, Cancer research.
[24] M. Schwab,et al. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. , 1998, Oncogene.
[25] A. Pession,et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] F. Westermann,et al. Ataxin-2 promotes apoptosis of human neuroblastoma cells , 2003, Oncogene.
[27] R. Green,et al. Comparison of sample preparation methods for ChIP-chip assays. , 2006, BioTechniques.
[28] E. Prochownik,et al. The Ever Expanding Role for c-Myc in Promoting Genomic Instability , 2007, Cell cycle.
[29] Wolfgang Huber,et al. arrayMagic: two-colour cDNA microarray quality control, preprocessing , 2005, Bioinform..
[30] Barbara Hero,et al. Neuroblastoma: biology and molecular and chromosomal pathology. , 2003, The Lancet. Oncology.
[31] J Pritchard,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Ishii,et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. , 2005, Cancer cell.
[33] M. Eilers,et al. Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.
[34] W. Sadee,et al. Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line. , 1987, Cancer research.
[35] H. Sather,et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.
[36] Roland Eils,et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling , 2004 .
[37] W. London,et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Philip R. Gafken,et al. Myc influences global chromatin structure , 2006, The EMBO journal.
[39] F. Speleman,et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. , 2006, Cancer research.
[40] M. Schwab,et al. MycN sensitizes neuroblastoma cells for drug-induced apoptosis , 1999, Oncogene.
[41] J. A. Hickman,et al. Why does stage 4s neuroblastoma regress spontaneously? , 1994, The Lancet.
[42] H. Varmus,et al. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture , 1985, Nature.
[43] Michael Baudis,et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] N. Cheung,et al. The MYCN enigma: significance of MYCN expression in neuroblastoma. , 2006, Cancer research.
[45] Teuvo Kohonen,et al. Self-Organizing Maps, Second Edition , 1997, Springer Series in Information Sciences.
[46] Kathryn A. O’Donnell,et al. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.
[47] G. Mohapatra,et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.
[48] P. Ambros,et al. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. , 2001, Medical and pediatric oncology.
[49] Alexander E. Kel,et al. TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..
[50] M. Eilers,et al. Mechanisms of transcriptional repression by Myc. , 2006, Current topics in microbiology and immunology.
[51] M Schwab,et al. N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.